Fast Track designation de-risks the regulatory pathway and signals FDA engagement, but the key catalyst remains the NDA submission and eventual approval. Monitor for NDA filing timing and any Phase 3 data readouts.
Price Chart
Executive Summary
Telix Pharmaceuticals announced that the FDA granted Fast Track designation for its BiPASS program, which evaluates 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. The designation facilitates more frequent FDA engagement and may enable expedited NDA review. Telix recently completed enrollment in the Phase 3 BiPASS study and is planning an NDA submission.
Key Facts
- FDA granted Fast Track designation for Telix's BiPASS program (pre-biopsy prostate cancer imaging).
- BiPASS evaluates 68Ga-PSMA-PET imaging in combination with MRI for prostate cancer detection prior to biopsy.
- Telix recently completed enrollment in the Phase 3 BiPASS study.
- Fast Track may enable expedited review of the planned NDA.
- Prior studies (PRIMARY and PRIMARY2) showed combining 68Ga-PSMA-PET with MRI can reduce unnecessary biopsies by almost 50%.
- More than 3 million prostate biopsies are performed globally each year, with up to 75% producing a negative result.
Financial Impact
No financial figures provided in the filing. The BiPASS program, if approved, would broaden access to 68Ga-PSMA-PET imaging for a substantially larger patient population, potentially expanding Telix's commercial diagnostic revenue.
Risk Factors
- The use of Illuccix and Gozellix in the pre-biopsy setting remains investigational and has not been approved by the FDA.
- No guarantee of NDA approval or commercial success in the pre-biopsy indication.
- Competition from other prostate cancer imaging modalities could limit market uptake.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-063875 |
| Document: a20260930bipassftvfinala.htm | 0001628280-26-063875 |
| Document: 0001628280-26-063875-index-headers.html | 0001628280-26-063875 |
| Document: 0001628280-26-063875-index.html | 0001628280-26-063875 |
| Document: 0001628280-26-063875.txt | 0001628280-26-063875 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | 6-K | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $8.99 (−10.37%) |
Oct 20, 2026 5d ago | Press Release | $10.03 $9.54 | ▼ −4.89% | ▼ −3.70% | $8.99 (−10.37%) |
Sep 29, 2026 26d ago | 6-K | $10.97 $10.72 | ▼ −2.28% | ▼ −2.46% | $8.99 (−18.05%) |
Sep 21, 2026 5w ago | 6-K | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $8.99 (−20.51%) |
Sep 20, 2026 5w ago | Press Release | $11.31 $11.95 | ▲ +5.66% | ▲ +5.67% | $8.99 (−20.51%) |
Sep 14, 2026 6w ago | 6-K | $12.83 $11.83 | ▼ −7.79% | ▼ −7.35% | $8.99 (−29.93%) |
Sep 14, 2026 6w ago | Press Release | $11.78 $12.83 | ▲ +8.91% | ▲ +9.37% | $8.99 (−23.68%) |
Sep 1, 2026 7w ago | 6-K | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $8.99 (−21.48%) |
Sep 1, 2026 7w ago | Press Release | $11.45 $11.74 | ▲ +2.53% | ▲ +1.49% | $8.99 (−21.48%) |
Aug 19, 2026 9w ago | 6-K | $12.42 $11.33 | ▼ −8.78% | ▼ −9.19% | $8.99 (−27.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers